Groupe Serb

Serb Pharmaceuticals is a global specialty pharmaceutical group focused on critical care, emergency medicine, and rare diseases. The company is a world leader in the development and commercialization of life-saving antidotes used to treat chemical, biological, and radiological exposures. Following its transformative acquisition of BTG Specialty Pharmaceuticals in 2021, the group has established a significant presence in North America and expanded its portfolio of high-value biologics. Its commercial portfolio includes essential brands such as CroFab for snake bites, DigiFab for digoxin toxicity, and Voraxaze for methotrexate toxicity. Serb operates as a fully integrated entity with internal expertise in R&D, manufacturing, and global distribution to hospitals and government agencies.